Relay Total Debt To Capitalization from 2010 to 2025

RLAY Stock  USD 3.41  0.16  4.92%   
Relay Therapeutics Total Debt To Capitalization yearly trend continues to be fairly stable with very little volatility. Total Debt To Capitalization is likely to outpace its year average in 2025. During the period from 2010 to 2025, Relay Therapeutics Total Debt To Capitalization regression line of annual values had r-squared of  0.15 and arithmetic mean of  0.01. View All Fundamentals
 
Total Debt To Capitalization  
First Reported
2010-12-31
Previous Quarter
0.05869824
Current Value
0.0616
Quarterly Volatility
0.05228676
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Relay Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Relay Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 36.5 M, Interest Income of 36.5 M or Depreciation And Amortization of 4 M, as well as many indicators such as Price To Sales Ratio of 55.88, Dividend Yield of 0.0 or PTB Ratio of 0.94. Relay financial statements analysis is a perfect complement when working with Relay Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Relay Therapeutics Correlation against competitors.
For more information on how to buy Relay Stock please use our How to Invest in Relay Therapeutics guide.

Latest Relay Therapeutics' Total Debt To Capitalization Growth Pattern

Below is the plot of the Total Debt To Capitalization of Relay Therapeutics over the last few years. It is Relay Therapeutics' Total Debt To Capitalization historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Relay Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Debt To Capitalization10 Years Trend
Slightly volatile
   Total Debt To Capitalization   
       Timeline  

Relay Total Debt To Capitalization Regression Statistics

Arithmetic Mean0.01
Geometric Mean0.01
Coefficient Of Variation665.06
Mean Deviation0.03
Median(0)
Standard Deviation0.05
Sample Variance0
Range0.226
R-Value0.39
Mean Square Error0
R-Squared0.15
Significance0.14
Slope0
Total Sum of Squares0.04

Relay Total Debt To Capitalization History

2025 0.0616
2024 0.0587
2023 0.0664
2022 0.0573
2021 0.0249
2020 0.031
2019 -0.16

About Relay Therapeutics Financial Statements

Relay Therapeutics investors use historical fundamental indicators, such as Relay Therapeutics' Total Debt To Capitalization, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Relay Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Debt To Capitalization 0.06  0.06 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Relay Stock Analysis

When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.